JHJunsong Han

Junsong Han

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Junsong Han has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Yichun Xu

    National Engineering Research Center for Biochip at Shanghai and Shanghai Biochip Limited Corporation, Shanghai, China

    6 shared publications
  • Jiajing Zhou

    National Engineering Research Center for Biochip at Shanghai and Shanghai Biochip Limited Corporation, Shanghai, China

    4 shared publications
  • Jun Su

    Shanghai National Engineering Research Center for Biochip at Shanghai and Shanghai Biochip Limited Corporation, Shanghai, China

    4 shared publications
  • Yi Gong

    Shanghai National Engineering Research Center for Biochip at Shanghai and Shanghai Biochip Limited Corporation, Shanghai, China

    3 shared publications
  • Congmeng Zhang

    Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    2 shared publications
  • Guanjin Wu

    Department of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

    2 shared publications

Latest Publications

  • Open Access

    Hypochlorite sensing and real-time imaging with XY-01: A red-emitting fluorescent turn-on probe for living cells and colorectal cancer organoids

    by Yichun Xu, Zhihua Chen, Jun Su, Yanting Ding, Jiajing Zhou, Jiawei Zhao, Zhiyuan He, Yi Gong, Zhai Cai, Lei Cui, et al.

    Hypochlorite (ClO⁻), a major reactive oxygen species generated in inflammation, is a potent biological oxidant involved in diverse physiological and pathological processes; therefore, sensitive detection of ClO⁻ is important for understanding disease pathophysiology and supporting early diagnosis and prevention. Here, we aimed to develop a physiologically compatible fluorescent tool for specific ClO⁻ sensing and imaging. We designed and synthesized a novel A–D–A type molecular fluorescent probe, XY-01, and characterized it by NMR, HRMS, UV–Vis and fluorescence spectroscopy. XY-01 operates through ClO⁻-triggered oxidation of a thioformyl group (C=S) to a carbonyl (C=O), which restores intramolecular charge transfer and produces a prominent fluorescence turn-on signal. In PBS (pH 7.4), XY-01 responded to ClO⁻ within 1 min with strong red emission at 666 nm and a large Stokes shift (~167 nm), showed high selectivity against common ions and reactive species, and achieved a detection limit of 3.39 µM within the biologically relevant range. Cytotoxicity assays indicated negligible toxicity, enabling real-time confocal imaging of ClO⁻ distribution in HCT-116 cells and colorectal cancer organoids. Collectively, XY-01 is a simple, sensitive, and low-toxicity probe that provides a promising platform for optical sensing and imaging of hypochlorite in living cells and organoids.

  • Open Access

    Application and prospects of lung organ-on-a-chip in the development of new drugs

    by Jun Su, Jingjing Qiu, Jiaxu Meng, Yi Gong, Yichun Xu, Junsong Han

    Respiratory disease, such as lung cancer, is a major risk factor that seriously endangers human health. In the development of new drugs, conventional precl


  • Roles of MT-ND1 in Cancer

    by Yi-Chun Xu, Jun Su, Jia-Jing Zhou, Qing Yuan, Jun-Song Han

    The energy shift toward glycolysis is one of the hallmarks of cancer. Complex I is a vital enzyme complex necessary for oxidative phosphorylation. The mitochondrially encoded NADH: ubiquinone oxidoreductase core subunit 1 (MT-ND1) is the largest subunit coded by mitochondria of complex I. The present study summarizes the structure and biological function of MT-ND1. From databases and literature, the expressions and mutations of MT-ND1 in a variety of cancers have been reviewed. MT-ND1 may be a biomarker for cancer diagnosis and prognosis. It is also a potential target for cancer therapy.


  • Open Access

    Correction: Molecular fingerprints of nuclear genome and mitochondrial genome for early diagnosis of lung adenocarcinoma

    by Yichun Xu, Yong Yang, Yichao Wang, Jun Su, Tianlong Chan, Jiajing Zhou, Yi Gong, Ke Wang, Yifeng Gu, Congmeng Zhang, et al.

  • Open Access

    Molecular fingerprints of nuclear genome and mitochondrial genome for early diagnosis of lung adenocarcinoma

    by Yichun Xu, Yong Yang, Yichao Wang, Jun Su, Tianlong Chan, Jiajing Zhou, Yi Gong, Ke Wang, Yifeng Gu, Congmeng Zhang, et al.

    Background: Lung adenocarcinoma (LUAD) is the most prevalent subtype of lung cancer with high morbidity and mortality rates. Due to the heterogeneity of LUAD, its characteristics remain poorly understood. Exploring the clinical and molecular characteristics of LUAD is challenging but vital for early diagnosis. Methods: This observational and validation study enrolled 80 patients and 13 healthy controls. Nuclear and mtDNA-captured sequencings were performed. Results: This study identified a spectrum of nuclear and mitochondrial genome mutations in early-stage lung adenocarcinoma and explored their association with diagnosis. The correlation coefficient for somatic mutations in cfDNA and patient-matched tumor tissues was high in nuclear and mitochondrial genomes. The mutation number of highly mutated genes was evaluated, and the Least Absolute Shrinkage and Selection Operator (LASSO) established a diagnostic model. Receiver operating characteristic (ROC) curve analysis explored the diagnostic ability of the two panels. All models were verified in the testing cohort, and the mtDNA panel demonstrated excellent performance. This study identified somatic mutations in the nuclear and mitochondrial genomes, and detecting mutations in cfDNA displayed good diagnostic performance for early-stage LUAD. Moreover, detecting somatic mutations in the mitochondria may be a better tool for diagnosing early-stage LUAD. Conclusions: This study identified specific and sensitive diagnostic biomarkers for early-stage LUAD by focusing on nuclear and mitochondrial genome mutations. This also further developed an early-stage LUAD-specific mutation gene panel for clinical utility. This study established a foundation for further investigation of LUAD molecular pathogenesis.


  • Open Access

    Quantitative detection of circulating MT-ND1 as a potential biomarker for colorectal cancer

    by Yichun Xu, Jiajing Zhou, Qing Yuan, Jun Su, Qian Li, Xiaoliang Lu, Liwen Zhang, Zhai Cai, Junsong Han

    Liquid biopsy represents a diagnostic and monitoring tool and the circulating cell-free mitochondrial DNA (mtDNA) plays a vital role in tumor diagnosis and dynamic assessment. Colorectal cancer (CRC) is one of the most common fatal cancers worldwide. Mitochondrially encoded NADH dehydrogenase subunit 1 (MT-ND1) encodes the biggest subunit of respiratory complex I of mtDNA, and mutations in the MT-ND1 are common in CRC. We sought to determine if mutations in circulating MT-ND1 could be a potential biomarker for colorectal cancer. In this study, twenty-two CRC patients at Zhujiang Hospital were included. We mainly used droplet digital PCR to determine the mutation status of MT-ND1, combined with clinical data. In the experiment in vivo, cell-free mtDNA generally presented high concordance with tumor tissues. By quantitative PCR, the MT-ND1 content of plasma in CRC patients was significantly higher than that in healthy individuals (58.01 vs. 0.64, p=0.027). The detection of circulating MT-ND1 content and variants (m.3606 A>G, m.3970 C>T, m.4071 C>T, m.4086 C>T) in cfDNA showed a good correlation with predicted tumor response and progression to chemotherapy. In conclusion, the content and variants of circulating MT-ND1 may become a versatile tool for the diagnosis and monitoring of colorectal cancer.


  • Open Access

    eRNAs and Superenhancer lncRNAs Are Functional in Human Prostate Cancer

    by Xiaona Zhang, Panpan Pang, Min Jiang, Qunfa Cao, Huili Li, Yi Xu, Yao Li, Xue Chen, Junsong Han

    Prostate cancer (PCa) is one of the most commonly diagnosed cancers in males worldwide. lncRNAs (long noncoding RNAs) play a significant role in the occurrence and development of PCa. eRNAs (enhancer RNAs) and SE-lncRNAs (superenhancer lncRNAs) are important elements of lncRNAs, but the role of eRNAs and SE-lncRNAs in PCa remains largely unclear. In this work, we identified 681 eRNAs and 292 SE-lncRNAs that were expressed differentially in PCa using a microarray. We also found that eRNAs transcribed from active open chromatin had significantly higher expression than those from active closed chromatin, and SE-lncRNAs had a little higher expression than eRNAs. Next, we constructed a transcriptional regulation network that eRNA-related enhancer and the target genes shared the same TF-binding motifs. Further, we investigated whether CTCF played a role in mediating the transcriptional regulation network. eRNAs, especially those that regulate androgen response genes, may be candidates for prognostic biomarkers and therapy targets. Our work provides a new perspective for developing medical treatments and therapies for prostate cancer.


  • Association of TOX3 polymorphisms with breast cancer: A meta-analysis

    by Yichun Xu, Qing Yuan, Jiajing Zhou, Xinnan Chang, Ke Wang, Junsong Han